Please login to the form below

Not currently logged in
Email:
Password:

Radicava

This page shows the latest Radicava news and features for those working in and with pharma, biotech and healthcare.

Biogen picks up another drug from wide-ranging Ionis alliance

Biogen picks up another drug from wide-ranging Ionis alliance

It was joined last year by Mitsubishi Tanabe Pharma’s Radicava/Radicut (edaravone) last year, which provides another options, but there is still a desperate need for additional therapies.

Latest news

  • Mitsubishi buys Israel's NeuroDerm for $1.1bn Mitsubishi buys Israel's NeuroDerm for $1.1bn

    The Parkinson's disease candidates will extend Mitsubishi's CNS portfolio in the US, which will see a major launch next month when the Japanese company introduces Radicava (edaravone), a new

  • FDA clears new ALS drug Radicava ahead of schedule FDA clears new ALS drug Radicava ahead of schedule

    Patients with the chronic neurodegenerative disease amyotrophic lateral sclerosis (ALS) have a new treatment option in the US after the FDA approved Mitsubishi Tanabe Pharma's Radicava (edaravone). ... MT Pharma America says it intends to launch Radicava

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...